MRGPRD

Across TCGA pan-cancer cohorts, MRGPRD RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MRGPRD’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MRGPRD RNA is repressed in tumor relative to normal tissue. In most cancer types MRGPRD is over-expressed in tumor, although a few such as BLCA and STAD show the opposite, repressed pattern.

BLCA, STAD, and COAD are the cancer types where MRGPRD tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRGPRD RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−0.362	.005	6	view →
STAD	All	All	−0.226	.007	5	view →
COAD	All	II,III,IV	−0.159	.003	4	view →
READ	Female	All	−0.660	.008	2	view →
UCEC	All	All	−0.293	.011	2	view →
PRAD	All	All	−0.178	<.001	2	view →
KICH	All	All	−0.037	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MRGPRD–BLCA

Open the BLCA breakdown →